Compare Paycom Software Inc (PAYC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Paycom Software (PAYC) trades at $232.22, up 3.86% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The stock shows bullish technical signals, with support near $226 and resistance at $232. Fundamentally, PAYC maintains robust profitability with a 22.78% net margin and 10% revenue growth in Q2 2026, though its P/E of 24.33 suggests a premium valuation. Positive sentiment is driven by institutional buying and analyst coverage, with 47% recommending Buy.

Outlook: PAYC's earnings momentum and operational efficiency support upside, but risks include premium valuation pressure and labor market sensitivity. The consensus price target of $207.75 implies caution, yet raised guidance and buybacks provide tailwinds. Investors should weigh strong execution against macroeconomic headwinds affecting payroll demand.

Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.

REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.